Ninein, a candidate gene for ethanol anxiolysis, shows complex exon-specific expression and alternative splicing differences between C57BL/6J and DBA/2J mice

Ethanol’s anxiolytic actions contribute to increased consumption and the development of Alcohol Use Disorder (AUD). Our laboratory previously identified genetic loci contributing to the anxiolytic-like properties of ethanol in BXD recombinant inbred mice, derived from C57BL/6J (B6) and DBA/2J (D2) p...

Full description

Bibliographic Details
Published in:	Frontiers in Genetics
Main Authors:	E. R. Gnatowski, J. L. Jurmain, M. G. Dozmorov, J. T. Wolstenholme, M. F. Miles
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-09-01
Subjects:	Ninein alternative splicing RNAseq exon skipping ethanol anxiety
Online Access:	https://www.frontiersin.org/articles/10.3389/fgene.2024.1455616/full

Similar Items

Loss of ninein interferes with osteoclast formation and causes premature ossification
by: Thierry Gilbert, et al.
Published: (2024-06-01)

Ninein is essential for apico-basal microtubule formation and CLIP-170 facilitates its redeployment to non-centrosomal microtubule organizing centres
by: Deborah A. Goldspink, et al.
Published: (2017-01-01)

MSI expresso: a software for determining MSI status and detecting MSI-related transcription events from RNA sequencing data
by: Emmanuel Tubacher, et al.
Published: (2025-04-01)

Analysis of Exon Skipping Applicability for Dysferlinopathies
by: Jamie Leckie, et al.
Published: (2025-01-01)

CRISPR-induced exon skipping is dependent on premature termination codon mutations
by: Tingting Sui, et al.
Published: (2018-10-01)

Upper Limb Changes in DMD Patients Amenable to Skipping Exons 44, 45, 51 and 53: A 24-Month Study
by: Claudia Brogna, et al.
Published: (2023-04-01)

Polyquaternium-mediated delivery of morpholino oligonucleotides for exon-skipping in vitro and in mdx mice
by: Mingxing Wang, et al.
Published: (2017-01-01)

CRISPR/Cas9 disruption of EpCAM Exon 2 results in cell-surface expression of a truncated protein targeted by an EpCAM specific T cell engager
by: Andisheh Bagheri, et al.
Published: (2022-03-01)

Antisense‐mediated exon skipping: a therapeutic strategy for titin‐based dilated cardiomyopathy
by: Michael Gramlich, et al.
Published: (2015-03-01)

Prevention of early-onset cardiomyopathy in Dmd exon 52–54 deletion mice by CRISPR-Cas9-mediated exon skipping
by: Matthew Rok, et al.
Published: (2023-09-01)

Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trialResearch in context
by: Yang Xia, et al.
Published: (2025-03-01)

Networking to Optimize <i>Dmd</i> exon 53 Skipping in the Brain of <i>mdx52</i> Mouse Model
by: Mathilde Doisy, et al.
Published: (2023-12-01)

Possibility of exon skipping therapy for Duchenne muscular dystrophy in Russian patients: present and future
by: E. V. Zinina, et al.
Published: (2024-09-01)

Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency
by: HaiFang Yin, et al.
Published: (2013-01-01)

DMD antisense oligonucleotide mediated exon skipping efficiency correlates with flanking intron retention time and target position within the exon
by: Remko Goossens, et al.
Published: (2023-12-01)

Identified eleven exon variants in PKD1 and PKD2 genes that altered RNA splicing by minigene assay
by: Xuyan Liu, et al.
Published: (2023-07-01)

Reverse complementary matches simultaneously promote both back-splicing and exon-skipping
by: Dong Cao
Published: (2021-08-01)

The exon-skipping oligonucleotide, KitStop, depletes tissue-resident mast cells in vivo to ameliorate anaphylaxis
by: Barry A. Hedgespeth, et al.
Published: (2023-01-01)

Systemic administration of the antisense oligonucleotide NS‐089/NCNP‐02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trial
by: Takami Ishizuka, et al.
Published: (2023-06-01)

Use of savolitinib as neoadjuvant therapy for non–small cell lung cancer patient with MET exon 14 skipping alterations: A case report
by: Yu Zhang, et al.
Published: (2022-09-01)

Twelve exonic variants in the SLC12A1 and CLCNKB genes alter RNA splicing in a minigene assay
by: Qing Xin, et al.
Published: (2022-08-01)

Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report
by: Siqi Xiang, et al.
Published: (2023-11-01)

Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies
by: Sally C.M. Lau, MD, MPH, et al.
Published: (2023-10-01)

Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14  Skipping Mutation
by: Lung Cancer Specialty Committee of Chinese Elderly Health Care Association
Published: (2023-06-01)

Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models
by: Christa L Tanganyika-de Winter, et al.
Published: (2012-01-01)

Challenges in Amplicon-Based DNA NGS Identification of MET Exon 14 Skipping Events in Non-Small Cell Lung Cancers
by: Magdalena Jurkiewicz, et al.
Published: (2025-02-01)

Cell-mediated exon skipping normalizes dystrophin expression and muscle function in a new mouse model of Duchenne Muscular Dystrophy
by: Francesco Galli, et al.
Published: (2024-03-01)

Successful Tepotinib Treatment in MET Exon 14 Skipping Mutation‐Positive Lung Adenocarcinoma With Idiopathic Pulmonary Fibrosis Through Nintedanib Combination
by: Yoshiki Kato, et al.
Published: (2025-06-01)

Oxytocin accelerates tight junction formation and impairs cellular migration in 3D spheroids: evidence from Gapmer-induced exon skipping
by: Benjamin Jurek, et al.
Published: (2022-10-01)

A survey of computational methods in transcriptome-wide alternative splicing analysis
by: Wang Jianbo, et al.
Published: (2015-03-01)

The X‐linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45–47
by: Christopher R. Heier, et al.
Published: (2023-04-01)

RNA-Seq Analysis of an Antisense Sequence Optimized for Exon Skipping in Duchenne Patients Reveals No Off-Target Effect
by: Claire Domenger, et al.
Published: (2018-03-01)

Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study
by: Chien-Hung Gow, et al.
Published: (2023-03-01)

Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non‐small cell lung cancer: A case report
by: Satoshi Ikeo, et al.
Published: (2023-04-01)

Modeling Patient-Specific Muscular Dystrophy Phenotypes and Therapeutic Responses in Reprogrammed Myotubes Engineered on Micromolded Gelatin Hydrogels
by: Florian Barthélémy, et al.
Published: (2022-04-01)

Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report
by: Rongzhen Li, et al.
Published: (2024-11-01)

Tween 85-Modified Low Molecular Weight PEI Enhances Exon-Skipping of Antisense Morpholino Oligomer In Vitro and in mdx Mice
by: Mingxing Wang, et al.
Published: (2017-12-01)

Ensemble-Learning and Feature Selection Techniques for Enhanced Antisense Oligonucleotide Efficacy Prediction in Exon Skipping
by: Alex Zhu, et al.
Published: (2023-06-01)

Oligonucleotide Enhancing Compound Increases Tricyclo-DNA Mediated Exon-Skipping Efficacy in the Mdx Mouse Model
by: Flavien Bizot, et al.
Published: (2023-02-01)

Identified five variants in CFTR gene that alter RNA splicing by minigene assay
by: Bingying Zhang, et al.
Published: (2025-03-01)